---
figid: PMC9664612__12885_2022_10221_Fig1_HTML
figtitle: Venetoclax combined with low dose cytarabine for the treatment of favourable
  risk adult acute myeloid leukaemia
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9664612
filename: 12885_2022_10221_Fig1_HTML.jpg
figlink: /pmc/articles/PMC9664612/figure/Fig1/
number: F1
caption: 'VICTOR trial schema VICTOR trial schema showing the patient pathway highlighting
  treatment decisions depending on disease status. #, cycles; CR, complete remission/response;
  DA, daunorubicin; DAGO, daunorubicin, cytarabine and gemtuzumab ozogamicin; FLAG-IDA,
  fludarabine, cytarabine and idarubicin; HIDAC, high-dose cytarabine; LDAC, low-dose
  cytarabine; MRD, minimal residual disease; R, randomisation; VEN, venetoclax'
papertitle: 'Venetoclax combined with low dose cytarabine compared to standard of
  care intensive chemotherapy for the treatment of favourable risk adult acute myeloid
  leukaemia (VICTOR): Study protocol for an international, open-label, multicentre,
  molecularly-guided randomised, phase II trial.'
reftext: Richard Dillon, et al. BMC Cancer. 2022;22:1174.
year: '2022'
doi: 10.1186/s12885-022-10221-2
journal_title: BMC Cancer
journal_nlm_ta: BMC Cancer
publisher_name: BioMed Central
keywords: Clinical trial | Acute myeloid leukaemia | Bayesian non-inferiority design
  | Adaptive design | Venetoclax | Low-dose cytarabine
automl_pathway: 0.7799512
figid_alias: PMC9664612__F1
figtype: Figure
redirect_from: /figures/PMC9664612__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9664612__12885_2022_10221_Fig1_HTML.html
  '@type': Dataset
  description: 'VICTOR trial schema VICTOR trial schema showing the patient pathway
    highlighting treatment decisions depending on disease status. #, cycles; CR, complete
    remission/response; DA, daunorubicin; DAGO, daunorubicin, cytarabine and gemtuzumab
    ozogamicin; FLAG-IDA, fludarabine, cytarabine and idarubicin; HIDAC, high-dose
    cytarabine; LDAC, low-dose cytarabine; MRD, minimal residual disease; R, randomisation;
    VEN, venetoclax'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IDUA
  - CD48
  - AKR1A1
  - ARMC9
  - FLT3
  - FUT3
  - BCR
  - key
  - ida
  - CycE
  - cyc
  - arm
  - ven
  - if
  - CR
  - da
  - nAChRalpha2
  - Is
  - ali
  - alpha-Est7
  - 'On'
  - Molecular failure
---
